<unk>  is a random polymer (average molecular mass 6.4 kD) composed of four amino acids found in myelin basic protein. The mechanism of action for<unk>  is not fully elucidated. It is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS. Administration of<unk>  shifts the population of T cells from proinflammatory Th1 T-cells to regulatory Th2 T-cells that suppress the inflammatory response. Given its resemblance to myelin basic protein,<unk>  may act as a decoy, diverting an autoimmune response against myelin. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis (EAE), a condition induced in several animal species through immunization against central nervous system derived material containing myelin and often used as an experimental animal model of MS. Studies in animals and in vitro systems suggest that upon its administration,<unk> -specific regulatory T cells (Tregs) are induced and activated in the periphery, inhibiting the inflammatory reaction to myelin basic protein. The integrity of the blood-brain barrier, however, is not appreciably affected by<unk> , at least not in the early stages of treatment.<unk>  has been shown in clinical trials to reduce the number and severity of multiple sclerosis exacerbations.
Glatiramer acetate
Riluzole
Fingolimod
Anakinra
Tocilizumab
Benralizumab
Atezolizumab
Satralizumab